Stock listing

NASDAQ:RNAC Cartesian Therapeutics, Inc. Stock

Home listing (NASDAQ) of Cartesian Therapeutics, Inc.

Follow Cartesian Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:RNAC

$6.14 USD -0.16 (-2.5%)

Close on Nov 20, 2026

Past year -14.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$5.89 – $6.32 USDNov 20, 2026
Volume
279,308 sharesNov 20, 2026
Market cap
$187.3M USDAt the close on Nov 20, 2026 · price × 30.50M shares outstanding
52-week range
$5.60 – $11.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.00M USDMedian day 117,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Cartesian Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RNAC · Home$6.14 USD-0.16 (-2.5%)279,308$5.89$6.32$5.89$6.30Close on Nov 20, 2026
Frankfurt:1S70€5.15 EUR-0.50 (-8.8%)—€5.15€5.15€5.15€5.65Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RNAC · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$6.14-0.16-2.5%$5.89$6.32$5.89279,308
$6.30+0.18+2.9%$6.04$6.37$6.01170,208
$6.12+0.04+0.7%$6.12$6.24$5.89232,800
$6.08-0.27-4.3%$6.33$6.435$6.0697,893
$6.35-0.005-0.1%$6.39$6.40$6.16106,818
$6.355-0.525-7.6%$6.82$6.82$6.12264,906
$6.88-0.01-0.1%$6.95$7.09$6.70134,041
$6.89-0.13-1.9%$6.99$7.28$6.7693,438
$7.02-0.51-6.8%$7.66$7.905$6.87313,315
$7.53+0.75+11.1%$6.82$7.67$6.73121,514
$6.78-0.04-0.6%$6.85$6.91$6.46184,785
$6.82+0.41+6.4%$6.64$7.158$6.54280,642
$6.41+0.07+1.1%$6.37$6.68$6.3797,714
$6.34-0.15-2.3%$6.49$6.68$6.20114,729
$6.49-0.26-3.9%$6.72$6.755$6.4478,798
$6.75+0.06+0.9%$6.76$6.97$6.63112,263
$6.69+0.23+3.6%$6.43$6.73$6.29113,922
$6.46+0.18+2.9%$6.26$6.55$6.13118,818
$6.28+0.10+1.6%$6.21$6.31$6.07105,631
$6.18-0.23-3.6%$6.38$6.52$6.1185,800
$6.41-0.01-0.2%$6.33$6.642$6.2489,200
$6.42+0.025+0.4%$6.42$6.706$6.40106,000
$6.395+0.315+5.2%$6.09$6.525$6.071168,600
$6.08-0.19-3.0%$6.28$6.55$6.01201,500
$6.27-0.31-4.7%$6.62$6.65$6.25112,700
$6.58+0.24+3.8%$6.39$6.776$6.3986,800
$6.34-0.23-3.5%$6.55$6.69$6.33173,400
$6.57-0.42-6.0%$6.98$7.02$6.565218,600
$6.99-0.065-0.9%$7.03$7.147$6.95107,800
$7.055+0.235+3.4%$6.87$7.165$6.851114,500
$6.82+0.14+2.1%$6.68$6.82$6.50214,400
$6.68-0.07-1.0%$6.70$6.84$6.6086,400
$6.75-0.39-5.5%$7.15$7.23$6.75171,200
$7.14-0.22-3.0%$7.36$7.425$7.11226,200
$7.36+0.14+1.9%$7.32$8.05$7.29200,400
$7.22+0.01+0.1%$7.16$7.44$7.15175,700
$7.21-0.03-0.4%$7.31$7.57$7.15166,900
$7.24+0.03+0.4%$7.28$7.56$7.10157,800
$7.21-0.20-2.7%$7.32$7.345$7.01109,100
$7.41-0.21-2.8%$7.60$7.60$7.31158,600
$7.62-0.25-3.2%$7.86$7.87$7.415205,800
$7.87-0.21-2.6%$8.05$8.155$7.65117,000
$8.08+0.14+1.8%$8.03$8.32$7.95161,700
$7.94-0.09-1.1%$8.11$8.23$7.75361,400
$8.03+0.17+2.2%$7.88$8.26$7.66211,400
$7.86-0.05-0.6%$8.11$8.27$7.79164,400
$7.91+0.02+0.3%$7.95$8.03$7.72118,000
$7.89-0.15-1.9%$8.00$8.01$7.67113,300
$8.04-0.15-1.8%$8.19$8.262$7.955110,200
$8.19-0.24-2.8%$8.59$8.88$8.18123,100
$8.43-0.26-3.0%$8.53$8.53$8.25128,300
$8.69-0.26-2.9%$8.94$9.151$8.5694,200
$8.95-0.32-3.5%$9.11$9.26$8.7561,400
$9.27+0.15+1.6%$9.12$9.31$8.8968,400
$9.12+0.04+0.4%$9.19$9.50$8.80134,900
$9.08-0.22-2.4%$9.30$9.64$8.81128,500
$9.30+0.02+0.2%$9.16$9.479$8.86112,100
$9.28-0.32-3.3%$9.54$9.54$9.1490,800
$9.60-0.37-3.7%$9.93$10.61$9.5565,600
$9.97-0.22-2.2%$10.12$10.23$9.8061,800
$10.19-0.19-1.8%$10.30$10.36$10.0665,800
$10.38+0.32+3.2%$10.19$10.88$10.0597,568
$10.06+0.02+0.2%$10.05$10.29$9.50104,239
$10.04-0.19-1.9%$10.35$10.69$10.00163,900
$10.23-0.26-2.5%$10.34$10.43$9.86134,700

Splits

1 split · NASDAQ:RNAC · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
Ticker
NASDAQ:RNAC
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Cartesian Therapeutics, Inc. news

Cartesian Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 46 in all · newest Nov 5, 2026 · oldest 2020
Calls
9 calls with a replay · 9 with a transcript · latest Aug 17, 2023
Decks
52 decks · latest Sep 29, 2026

Where Cartesian Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RNAC · Home listing · This pageNASDAQUnited StatesUSD
LS Exchange:A407YSLS ExchangeGermanyEUR
Lang & Schwarz:A407YSLang & SchwarzGermanyEUR
BOATS:RNACBOATSUnited StatesUSD
gettex:1S70gettexGermanyEUR
Frankfurt:1S70FrankfurtGermanyEUR
Munich:1S70MunichGermanyEUR
Stuttgart:1S70StuttgartGermanyEUR

Valuation

EV/sales 112× against a median of 14.4×: the highest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$114.5M USD
P/E
Loss
EV/sales
112×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
Negative equity
Beta vs S&P 500
1.23

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Cartesian Therapeutics, Inc. · NASDAQ:RNACUS$187.3MUS$114.5Mn/a112×n/an/an/an/a1.23
AC Immune SA · NASDAQ:ACIUUS$193.9MUS$110.5Mn/a4.7×n/a6.0×−181.9%0.1×1.56
SillaJen, Inc. · KRX:215600US$193.5MUS$141.7Mn/a17.6×n/a2.6×−223.8%0.0×n/a
AN2 Therapeutics, Inc. · NASDAQ:ANTXUS$192.8MUS$128.4Mn/an/an/a2.5×n/a0.0×0.54
Artiva Biotherapeutics, Inc. · NASDAQ:ARTVUS$186.9M−US$123.1Mn/an/an/a0.6×n/a0.0×1.34
Inventage Lab, Inc. · KRX:389470US$185.9MUS$113.3Mn/a61.3×n/a2.8×−127.0%0.2×n/a
Inhibikase Therapeutics, Inc. · NASDAQ:IKTUS$185.2M−US$8.17Mn/an/an/a1.0×n/a0.0×1.50
Antengene Corporation Limited · HKEX:6996US$183.1MUS$107.1Mn/a6.8×n/a1.3×−227.0%0.3×n/a
Whitehawk Therapeutics, Inc. · NASDAQ:WHWKUS$181.2MUS$11.70Mn/an/an/a1.1×n/a0.0×1.35
Sol-Gel Technologies Ltd. · NASDAQ:SLGLUS$180.6MUS$137.0Mn/a95.4×n/a4.2×n/a0.0×0.67
Tanvex BioPharma, Inc. · TWSE:6541US$180.5MUS$225.7Mn/a11.3×n/a1.2×−222.8%0.4×n/a
Median of the othersUS$185.5MUS$111.9M14.4×1.9×−222.8%0.0×1.35

Forecasts

6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
33.67 USD · Analysts' mean
EPS, year to Dec 2026
-1.23 · 1 analyst
Revenue, year to Dec 2026
383.4K · 7 analysts

Team and board

Officers

OfficerRole
Carsten BrunnPresident, Chief Executive Officer, and Chairman, Board of Directors
Blaine DavisChief Financial Officer
Matthew BartholomaeGeneral Counsel, Secretary
Emily EnglishChief Operations Officer
Peter TraberHead of Research and Development

Board

DirectorRole
Carsten BrunnPresident, Chief Executive Officer, and Chairman, Board of Directors
Adrian Bot
Kemal Malik
Michael Singer
Nishan de Silva
Patrick Zenner
Timothy Barabe
Timothy Springer

Events

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−0.6%
Q2 2026Aug 6, 2026 · Before open+4.9%
Q1 2026Apr 30, 2026 · Before open−3.9%
Q4 2025Mar 9, 2026+24.8%
Q3 2025Nov 6, 2025 · Before open−1.6%
Q2 2025Aug 7, 2025 · Before open−6.6%
Q1 2025May 8, 2025 · Before open+2.7%
Q4 2024Mar 5, 2025 · Before open+0.5%
Q3 2024Nov 7, 2024 · Before open−0.4%
Q2 2024Aug 8, 2024 · Before open−9.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · Before open+0.2%
Q4 2023Mar 7, 2024 · Before open−8.0%
Q3 2023Nov 13, 2023 · After close+21.4%
Q2 2023Aug 17, 2023 · Before open+2.8%
Q1 2023May 4, 2023 · Before open−7.0%
Q4 2022Mar 2, 2023 · Before open−1.3%
Q3 2022Nov 3, 2022 · Before open+3.7%
Q2 2022Aug 4, 2022 · Before open+13.9%
Q1 2022May 5, 2022 · Before open+1.1%
Q4 2021Mar 10, 2022 · Before open0.0%

Open Events

Decks

DeckKindSlidesDate
2026 MGFA Scientific Session at AANEMConference14 slidesSep 29, 2026
Investor Presentation (September 2026)Investor deck33 slidesSeptember 2026
Investor Presentation (May 2026)Investor deck31 slidesMay 26, 2026
Investor Presentation (January 2026)Investor deck35 slidesJan 9, 2026
Investor Presentation (November 2025)Investor deck30 slidesNov 13, 2025
American Academy of Neurology 2025 Annual MeetingConference14 slidesApr 9, 2025
Investor Presentation (April 2025)Investor deck32 slidesApr 8, 2025
Investor Presentation (March 2025)Investor deck19 slidesMar 3, 2025
Investor Presentation (January 2025)Investor deck30 slidesJan 13, 2025
Corporate Update (December 2024)Corporate update18 slidesDec 3, 2024
Show 50 decks
DeckKindSlidesDate
2024 MGFA Scientific Session at AANEMConference21 slidesOct 15, 2024
Investor Presentation (August 2024)Investor deck31 slidesAug 8, 2024
Corporate Update (July 2024)Corporate update29 slidesJul 2, 2024
American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting 2024Conference20 slidesMay 10, 2024
Investor Presentation (May 2024)Investor deck30 slidesMay 8, 2024
Investor Presentation (April 2024)Investor deck26 slidesApr 9, 2024
Investor Presentation (March 2024)Investor deck25 slidesMarch 2024
Investor Presentation (March 2024)Investor deck25 slidesMarch 2024
6th European CAR T-Cell Meeting 2024Conference22 slidesFeb 26, 2024
Cell & Gene Therapy Innovation Summit 2024Conference26 slidesFeb 8, 2024
Investor Presentation (January 2024)Investor deck23 slidesJan 22, 2024
Merger or Acquisition (November 2023)Merger or acquisition24 slidesNov 13, 2023
Selecta Biosciences — Merger or Acquisition (November 2023)Merger or acquisition34 slidesNov 13, 2023
Selecta Biosciences — Technical Presentation (March 2023)Technical17 slidesMar 21, 2023
Selecta Biosciences — Investor Presentation (January 2023)Investor deck39 slidesJan 9, 2023
Selecta Biosciences — Investor Presentation (November 2022)Investor deck44 slidesNov 18, 2022
Selecta Biosciences — Investor Presentation (August 2022)Investor deck44 slidesAug 4, 2022
Selecta Biosciences — Investor Presentation (April 2022)Investor deck43 slidesApr 13, 2022
Selecta Biosciences — Investor Presentation (April 2022)Investor deck43 slidesApr 6, 2022
Selecta Biosciences — Investor Presentation (February 2022)Investor deck40 slidesFeb 16, 2022
Selecta Biosciences — Technical Presentation (November 2021)Technical18 slidesNov 8, 2021
Selecta Biosciences — Technical Presentation (September 2020)Technical13 slidesSep 30, 2020
Selecta Biosciences — Investor Presentation (June 2020)Investor deck29 slidesJun 18, 2020
Selecta Biosciences — Investor Presentation (January 2020)Investor deck24 slidesJan 13, 2020
Selecta Biosciences — Investor Presentation (November 2019)Investor deck24 slidesNov 19, 2019
Selecta Biosciences — Investor Presentation (September 2019)Investor deck24 slidesSep 30, 2019
Selecta Biosciences — J.P. Morgan Healthcare Conference 2019Conference26 slidesJan 7, 2019
Selecta Biosciences — American College of Rheumatology (ACR) Annual Meeting 2018Conference18 slidesOct 23, 2018
Selecta Biosciences — Jefferies Gene Therapy Summit 2018Conference27 slidesSep 27, 2018
Selecta Biosciences — Canaccord Genuity Presentation August 2018Conference33 slidesAug 9, 2018
Selecta Biosciences — Technical Presentation (June 2018)Technical14 slidesJun 15, 2018
Selecta Biosciences — Jefferies Healthcare Conference 2018Conference32 slidesJun 4, 2018
Selecta Biosciences — Technical Presentation (April 2018)Technical17 slidesApr 10, 2018
Selecta Biosciences — Needham Presentation (March 2018)Conference33 slidesMar 27, 2018
Selecta Biosciences — Investor Presentation (January 2018)Investor deck33 slidesJan 8, 2018
Selecta Biosciences — Stifel 2017 Healthcare ConferenceConference20 slidesNov 14, 2017
Selecta Biosciences — Q3 2017 Earnings PresentationEarnings24 slidesNov 7, 2017
Selecta Biosciences — Investor Presentation (June 2017)Investor deck38 slidesJun 21, 2017
Selecta Biosciences — Technical Presentation (June 2017)Technical26 slidesJun 15, 2017
Selecta Biosciences — Q1 2017 Earnings PresentationEarnings17 slidesMay 11, 2017

This page holds 50 of 52 decks. Open Decks

Open Decks

IPO

Went public as SELECTA BIOSCIENCES INC. Priced at US$14.00 a share. Final prospectus filed on Jun 23, 2016.

Price
US$14.00 a share
Shares offered
5,000,000 shares of common stock
Offering size
US$70 million
Listing
SELB on the Nasdaq Global Market
Underwriters
UBS Investment Bank, Stifel, Canaccord Genuity, Needham & Company · In the order on the cover
Shares delivered
On or about Jun 27, 2016

Steps

StepWhen
Draft sent to the SEC in confidenceNov 24, 2015
Filed publiclyMay 24, 2016
Amended twiceNewest Jun 20, 2016
Shares registered with an exchangeJun 8, 2016
Declared effective by the SECJun 21, 2016
Final prospectus, with the priceJun 23, 2016

Open IPO · From the cover of the final prospectus (424B4) filed Jun 23, 2016

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue2.80M38.9M26.0M110.8M85.1M16.6M6.68M903.0K207.0K8.08M
Cost of revenue1.55M2.04M42.7M47.7M45.2M15.3M
Gross profit2.80M38.9M26.0M108.7M85.1M16.6M6.68M903.0K207.0K8.08M
Research and development58.0M45.1M71.3M72.4M68.7M54.5M42.7M47.7M45.2M29.7M
Selling, general and administrative31.5M30.1M40.5M23.9M20.9M18.9M16.4M18.2M18.8M13.1M
Operating income-143.4M-43.9M-86.4M14.5M-4.60M-56.8M-52.5M-65.0M-63.8M-34.7M
Depreciation and amortization2.40M1.20M700.0K700.0K600.0K600.0K700.0K1.00M750.0K802.0K
EBITDA-141.0M-42.7M-85.7M15.2M-4.00M-56.2M-51.8M-64.0M-63.0M-33.9M
Interest expense02.83M3.03M2.84M1.56M1.52M1.49M1.21M1.25M
Income before tax-139.5M-77.1M-238.7M34.8M-9.72M-68.9M-55.4M-65.3M-65.3M-36.2M
Income tax-9.19M287.0K-19.0M-609.0K16.0M001304.0K455.0K
Net income-130.3M-77.4M-219.7M35.4M-25.7M-68.9M-55.4M-65.3M-65.3M-36.2M
Earnings per share, basic-5.02-4.48-49.760.24-0.22-0.68-1.22-2.92-3.20-3.89
Earnings per share, diluted-5.02-4.49-49.760.10-0.22-0.68-1.22-2.92-3.20-3.89

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents125.1M212.6M76.9M106.4M114.1M138.7M89.9M37.4M70.6M58.7M
Short-term investments028.2M14.0M0025.9M25.5M
Receivables1.11M872.0K5.87M6.60M9.91M7.22M5.00M063.0K215.0K
Inventory1.00M-2.04M0
Current assets129.3M216.6M90.7M148.1M144.4M151.3M96.7M42.1M98.7M86.8M
Property, plant and equipment12.2M9.91M2.11M2.79M2.14M1.40M1.22M2.13M2.09M2.05M
Goodwill48.2M48.2M48.2M000
Total assets296.4M435.0M305.1M165.9M159.9M165.4M99.6M44.5M101.1M89.3M
Accounts payable1.29M288.0K3.15M316.0K224.0K443.0K500.0K1.10M1.61M3.88M
Current liabilities14.9M23.0M68.2M25.1M72.3M81.5M34.9M35.1M11.0M13.7M
Long-term debt017.8M19.7M24.8M021.0M7.98M
Total debt014.0M11.0M37.9M35.3M35.3M19.3M21.4M21.0M12.0M
Total liabilities422.7M441.8M444.7M72.1M137.4M183.4M91.2M49.9M49.3M34.3M
Shareholders' equity-126.2M-6.80M-440.2M93.8M22.5M-18.0M8.40M-5.42M51.8M55.0M
Shares outstanding26.0M25.8M5.40M153.0M123.6M108.1M86.3M22.5M22.3M18.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-73.9M-23.7M-51.2M-31.6M-60.4M34.9M-51.4M-59.2M-52.0M-19.8M
Capital spending-5.45M-9.09M-206.0K-1.20M-1.08M-815.0K-47.0K-884.0K-733.0K-586.0K
Free cash flow-79.4M-32.8M-51.4M-32.8M-61.5M34.1M-51.5M-60.0M-52.8M-20.3M
Cash from investing-5.45M-8.74M34.6M-15.0M-17.1M-741.0K229.0K25.3M-2.10M-22.1M
Cash from financing-8.05M168.4M-13.1M39.2M52.9M14.4M105.0M697.0K66.0M67.7M
Dividends paid-184.0K-28.0K-25.5M-4.57M
Share buybacks0-6.17M189.0K161.0K184.0K28.0K196.0K180.0K71.8M
Change in cash-87.4M136.0M-29.8M-7.40M-24.6M48.5M53.9M-33.3M12.0M26.3M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
8-K · Current reportSep 29, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 22, 2026Big-stake noticeSEC
8-K · Current reportJun 17, 2026Meeting outcomeSEC
144 · Notice of proposed saleJun 9, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportJun 9, 2026Current reportSEC
144 · Notice of proposed saleJun 2, 2026Other filingsSEC
8-K · Current reportMay 26, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansApr 30, 2026Offer documentSEC
10-Q · Quarterly reportApr 30, 2026Quarterly reportSEC
8-K · Current reportApr 30, 2026ResultsSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 2, 2026Big-stake noticeSEC
8-K · Current reportMar 30, 2026Management or board changeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMar 13, 2026Big-stake noticeSEC
10-K · Annual reportMar 9, 2026Annual reportSEC
8-K · Current reportMar 9, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
144 · Notice of proposed saleJan 13, 2026Other filingsSEC
144 · Notice of proposed saleJan 9, 2026Other filingsSEC
8-K · Current reportJan 9, 2026Current reportSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 18, 2025Insider tradeSEC
8-K · Current reportDec 18, 2025Management or board changeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 2, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
144 · Notice of proposed saleNov 19, 2025Other filingsSEC
8-K · Current reportNov 13, 2025Current reportSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
8-K · Current reportOct 30, 2025Management or board changeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 28, 2025Insider tradeSEC
8-K · Current reportOct 21, 2025Management or board changeSEC
8-K · Current reportOct 8, 2025Management or board changeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
8-K · Current reportJun 16, 2025Meeting outcomeSEC
8-K · Current reportMay 30, 2025Current reportSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMay 8, 2025Offer documentSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
8-K · Current reportApr 29, 2025Management or board changeSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeApr 25, 2025Big-stake noticeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
8-K · Current reportApr 8, 2025Current reportSEC
4 · Change in ownershipMar 20, 2025Insider tradeSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
8-K · Current reportMar 13, 2025ResultsSEC
8-K · Current reportMar 3, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
8-K · Current reportJan 27, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 15, 2025Big-stake noticeSEC
4 · Change in ownershipJan 15, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveJan 14, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveJan 14, 2025Other filingsSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025Current reportSEC
POS AM · Amendment to an effective registrationJan 10, 2025Offer documentSEC
POS AM · Amendment to an effective registrationJan 10, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 10, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveJan 10, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveJan 10, 2025Other filingsSEC
424B7 · ProspectusJan 8, 2025Offer documentSEC
424B7 · ProspectusJan 8, 2025Offer documentSEC
424B3 · ProspectusJan 8, 2025Offer documentSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
CORRESP · Letter to the SECJan 6, 2025Other filingsSEC
CORRESP · Letter to the SECJan 6, 2025Other filingsSEC
CORRESP · Letter to the SECJan 6, 2025Other filingsSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 23, 2024Big-stake noticeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
UPLOAD · Letter from the SECDec 19, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 19, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 19, 2024Other filingsSEC
S-3 · Registration statementDec 13, 2024Offer documentSEC
S-3 · Registration statementDec 13, 2024Offer documentSEC
S-3 · Registration statementDec 13, 2024Offer documentSEC
4 · Change in ownershipDec 11, 2024Insider tradeSEC
144 · Notice of proposed saleDec 10, 2024Other filingsSEC
144 · Notice of proposed saleDec 9, 2024Other filingsSEC
8-K · Current reportDec 3, 2024Current reportSEC
4 · Change in ownershipNov 21, 2024Insider tradeSEC
4 · Change in ownershipNov 21, 2024Insider tradeSEC
4 · Change in ownershipNov 21, 2024Insider tradeSEC
144 · Notice of proposed saleNov 21, 2024Other filingsSEC
144 · Notice of proposed saleNov 20, 2024Other filingsSEC
144 · Notice of proposed saleNov 19, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedNov 18, 2024Big-stake noticeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
144 · Notice of proposed saleNov 18, 2024Other filingsSEC
144 · Notice of proposed saleNov 15, 2024Other filingsSEC
144 · Notice of proposed saleNov 15, 2024Other filingsSEC
144 · Notice of proposed saleNov 15, 2024Other filingsSEC
144 · Notice of proposed saleNov 14, 2024Other filingsSEC
144 · Notice of proposed saleNov 14, 2024Other filingsSEC
144 · Notice of proposed saleNov 14, 2024Other filingsSEC
S-8 · Registration statement for employee plansNov 7, 2024Offer documentSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedOct 15, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedOct 4, 2024Big-stake noticeSEC
4 · Change in ownershipOct 4, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveOct 2, 2024Other filingsSEC
424B7 · ProspectusOct 1, 2024Offer documentSEC
CORRESP · Letter to the SECSep 27, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedSep 27, 2024Big-stake noticeSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
8-K · Current reportSep 26, 2024Current reportSEC
8-K · Current reportSep 23, 2024Meeting outcomeSEC
CORRESP · Letter to the SECSep 20, 2024Other filingsSEC
S-1/A · Registration statement, amendedSep 20, 2024Offer documentSEC
UPLOAD · Letter from the SECSep 16, 2024Other filingsSEC
CORRESP · Letter to the SECSep 9, 2024Other filingsSEC
S-1/A · Registration statement, amendedSep 9, 2024Offer documentSEC
UPLOAD · Letter from the SECAug 29, 2024Other filingsSEC
DEF 14A · Proxy statementAug 16, 2024Meeting noticeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
SC 13G · Big-stake noticeAug 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
PRE 14A · Preliminary proxy statementAug 2, 2024Meeting noticeSEC
S-1 · Registration statementAug 2, 2024Offer documentSEC
DJul 17, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedJul 12, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedJul 5, 2024Big-stake noticeSEC
4 · Change in ownershipJul 5, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2024Insider tradeSEC
8-K · Current reportJul 2, 2024Material contractSEC
8-K · Current reportJun 17, 2024Management or board changeSEC
8-K · Current reportMay 22, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedMay 10, 2024Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024ResultsSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
8-K · Current reportApr 22, 2024Current reportSEC
3 · Initial statement of ownershipApr 19, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedApr 12, 2024Big-stake noticeSEC
4 · Change in ownershipApr 10, 2024Insider tradeSEC

This page holds 200 of 877 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Cartesian Therapeutics, Inc.’s releases · as of Oct 31, 2026

Common shares
30,503,005
Fully diluted
30,503,005

Fully diluted

LineSharesAs of
Common shares30,503,005Oct 31, 2026

Share count over time

CountShares
Oct 31, 202630,503,005

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Squarepoint Ops LLC2.26M7.4%US$16.3MSep 30, 2026
BlackRock808K2.7%US$5.83MSep 30, 2026
683 Capital Management, LLC751K2.5%US$5.41MSep 30, 2026
Vanguard740K2.4%US$5.34MSep 30, 2026
Fidelity370K1.2%US$2.67MSep 30, 2026
Two Sigma367K1.2%US$2.65MSep 30, 2026
Geode Capital343K1.1%US$2.47MSep 30, 2026
AQR Capital Management LLC287K0.94%US$2.07MSep 30, 2026
State Street262K0.86%US$1.89MSep 30, 2026
Marshall Wace, LLP244K0.80%US$1.76MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
UBS223K0.73%US$1.61MSep 30, 2026
Millennium222K0.73%US$1.6MSep 30, 2026
Janus Henderson207K0.68%US$1.49MSep 30, 2026
Privium Fund Management B.V.155K0.51%US$1.12MSep 30, 2026
CM Management, LLC120K0.39%US$865KSep 30, 2026
Northern Trust105K0.34%US$757KSep 30, 2026
Trexquant Investment LP74,6150.24%US$538KSep 30, 2026
ADAR1 Capital Management, LLC73,8770.24%US$533KSep 30, 2026
Renaissance Technologies72,2000.24%US$521KSep 30, 2026
Citadel70,0050.23%US$505KSep 30, 2026
Nuveen69,1930.23%US$499KSep 30, 2026
BNP Paribas65,7540.22%US$474KSep 30, 2026
Acadian Asset Management LLC63,2660.21%US$451KSep 30, 2026
Goldman Sachs51,5290.17%US$372KSep 30, 2026
Point72 Asset Management, L.P.47,7830.16%US$345KSep 30, 2026
Jump Financial, LLC37,9470.12%US$274KSep 30, 2026
Bank of America35,2350.12%US$254KSep 30, 2026
Walleye Capital LLC33,0970.11%US$239KSep 30, 2026
Schwab32,1550.11%US$232KSep 30, 2026
D. E. Shaw & Co., Inc.30,1850.10%US$218KSep 30, 2026
Bridgeway Capital Management, LLC29,9000.10%US$216KSep 30, 2026
Atlatl Advisers LLC28,5090.09%US$206KSep 30, 2026
BNY28,2130.09%US$203KSep 30, 2026
Susquehanna27,0070.09%US$195KSep 30, 2026
Twin Focus Capital Partners, LLC25,0000.08%US$180KSep 30, 2026
Empowered Funds, LLC25,0000.08%US$180KSep 30, 2026
AllianceBernstein22,1150.07%US$159KSep 30, 2026
Miller Financial Services LLC22,1100.07%US$159KSep 30, 2026
XTX Topco Ltd21,5110.07%US$155KSep 30, 2026
Ikarian Capital, LLC20,8070.07%US$150KSep 30, 2026
Ieq Capital, LLC20,7630.07%US$150KSep 30, 2026
Invesco19,6870.06%US$142KSep 30, 2026
Morgan Stanley16,2120.05%US$117KSep 30, 2026
Brevan Howard Capital Management LP16,0260.05%US$116KSep 30, 2026
Sei Investments Co15,9200.05%US$115KSep 30, 2026
Rhumbline Advisers15,1640.05%US$109KSep 30, 2026
Hrt Financial LP15,1380.05%US$109KSep 30, 2026
Cerity Partners LLC13,7550.05%US$99,174Sep 30, 2026
Dynamic Technology Lab Private Ltd13,6940.04%US$98,000Sep 30, 2026
CPP Investments13,6000.04%US$98,056Sep 30, 2026

This page holds 50 of 96 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund376K1.2%US$3.92MJun 30, 2026
Select Biotechnology Portfolio367K1.2%US$2.76MMay 31, 2026
iShares Russell 2000 ETF339K1.1%US$3.53MJun 30, 2026
Janus Henderson Small Cap Growth Alpha ETF195K0.64%US$1.52MJul 31, 2026
Vanguard Extended Market Index Fund170K0.56%US$1.77MJun 30, 2026
Fidelity Small Cap Index Fund144K0.47%US$1.12MJul 31, 2026
iShares Russell 2000 Value ETF94,8710.31%US$989KJun 30, 2026
Fidelity Extended Market Index Fund57,2540.19%US$432KMay 31, 2026
Vanguard Russell 2000 Index Fund53,4640.18%US$403KMay 31, 2026
iShares Micro-Cap ETF44,1240.14%US$460KJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Ultra-Small Company Market Fund32,5000.11%US$339KJun 30, 2026
Schwab Small-Cap Index Fund32,1180.11%US$251KJul 31, 2026
Master Small Cap Index Series29,7080.10%US$310KJun 30, 2026
College Retirement Equities Fund - Total Global Stock Account22,1600.07%US$231KJun 30, 2026
Clearwater Select Equity Fund21,2390.07%US$221KJun 30, 2026
Jacob Discovery Fund18,5000.06%US$139KMay 31, 2026
Nuveen Small Cap Blend Index Fund17,3200.06%US$135KJul 31, 2026
iShares Russell 2000 Growth ETF17,0530.06%US$178KJun 30, 2026
Fidelity Nasdaq Composite Index Fund16,6040.05%US$125KMay 31, 2026
Fidelity Series Total Market Index Fund16,3120.05%US$123KMay 31, 2026
Fidelity Small Cap Value Index Fund16,2710.05%US$170KJun 30, 2026
Fidelity Total Market Index Fund15,8960.05%US$120KMay 31, 2026
Goldman Sachs Absolute Return Tracker Fund12,3950.04%US$129KJun 30, 2026
EQ/2000 Managed Volatility Portfolio11,3970.04%US$119KJun 30, 2026
Nuveen Equity Index Fund11,2100.04%US$87,438Jul 31, 2026
EQ/Small Company Index Portfolio10,6480.03%US$111KJun 30, 2026
EQ/AB Small Cap Growth Portfolio9,2770.03%US$96,666Jun 30, 2026
Vanguard Russell 2000 Value Index Fund7,2390.02%US$54,582May 31, 2026
LVIP State Street Small-Cap Index Fund7,1260.02%US$74,253Jun 30, 2026
Small Cap Index Fund7,0100.02%US$73,044Jun 30, 2026
Global X Russell 2000 ETF6,2800.02%US$48,984Jul 31, 2026
ATM Small Cap Managed Volatility Portfolio5,4570.02%US$56,862Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund5,2070.02%US$54,257Jun 30, 2026
Small-Cap Index Portfolio4,7550.02%US$49,547Jun 30, 2026
Vanguard Balanced Index Fund4,5770.02%US$47,692Jun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio4,2900.01%US$44,702Jun 30, 2026
Bridge Builder Small/Mid Cap Value Fund3,6350.01%US$37,877Jun 30, 2026
Small Cap Index Fund3,5440.01%US$26,722May 31, 2026
NVIT Small Cap Index Fund3,1300.01%US$32,615Jun 30, 2026
1290 VT Micro Cap Portfolio2,985<0.01%US$31,104Jun 30, 2026
DWS Small Cap Index VIP2,091<0.01%US$21,788Jun 30, 2026
T. Rowe Price Small-Cap Index Fund1,978<0.01%US$20,611Jun 30, 2026
1290 VT Small Cap Value Portfolio1,876<0.01%US$19,548Jun 30, 2026
SA Small Cap Index Portfolio1,755<0.01%US$13,689Jul 31, 2026
iShares Russell Small/Mid-Cap Index Fund1,749<0.01%US$13,642Jul 31, 2026
Fidelity Small Cap Growth Index Fund1,479<0.01%US$15,411Jun 30, 2026
Victory Extended Market Index Fund1,475<0.01%US$11,505Jul 31, 2026
BlackRock Small Cap Index V.I. Fund1,463<0.01%US$15,244Jun 30, 2026
Vanguard Russell 2000 Growth Index Fund1,087<0.01%US$8,196May 31, 2026
PD Small-Cap Value Index Portfolio973<0.01%US$10,139Jun 30, 2026

This page holds 50 of 80 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Timothy A. Springer36.90%9.56MJan 13, 2025Schedule 13D
Squarepoint Ops LLC8.30%2.21MMar 9, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Carrie S. Cox
Other companies: Solventum Corporation (Director · Since at least Apr 1, 2024); Organon & Co. (Executive Board Chair · Since at least Jun 2, 2021); Texas Instruments Incorporated (Director · Since at least Jul 28, 2015); electroCore, Inc. (Director · Jun 21, 2018 – Jun 7, 2019 · Past); Cardinal Health, Inc. (Director · Nov 4, 2015 – Nov 9, 2022 · Past); Celgene Corporation (Director · Jul 1, 2015 – Nov 20, 2019 · Past)
Director · Nov 20, 2019 – Jan 2, 2025 · Past
Bradford D Dahms
Other companies: Jade Biosciences, Inc. (Chief Financial Officer · Since at least Jul 14, 2025); Theseus Pharmaceuticals Inc (President and CFO · Oct 6, 2021 – Feb 14, 2024 · Past)
Chief Financial Officer · Sep 3, 2019 – Jan 4, 2021 · Past
John Leaman
Other companies: Traws Pharma, Inc. (Director · Since at least Oct 1, 2025); Impel Neuropharma Inc (Chief Fin. & Business Officer · Apr 22, 2021 – Jan 26, 2022 · Past)
CFO, Treas. & Hd Corp Strategy · Oct 26, 2017 – Jun 15, 2018 · Past
Carsten Brunn
Other companies: Surface Oncology Inc (Director · Jun 28, 2022 – Jun 28, 2022 · Past)
President, Chief Executive Officer, and Chairman, Board of Directors · Since at least Dec 1, 2018
Göran Ando
Other companies: EyePoint, Inc. (Non-Executive Chairman · Since at least Jun 25, 2018)
Director · Apr 24, 2020 – Jan 2, 2023 · Past
Kemal Malik
Other companies: Acceleron Pharma Inc (Director · Jan 2, 2020 – Nov 19, 2021 · Past)
Director · Since at least Jul 1, 2024
Kevin Tan
Other companies: Solid Biosciences Inc. (CFO & Treasurer · Since at least Jan 9, 2023)
Chief Financial Officer · Sep 20, 2021 – Jan 3, 2022 · Past
Stephen Smolinski
Other companies: Avalo Therapeutics, Inc. (Chief Commercial Officer · Jan 3, 2022 – Jan 4, 2022 · Past)
Chief Commercial Officer · Oct 26, 2017 – Jan 2, 2020 · Past
Timothy Barabe
Other companies: Heartflow, Inc. (Director · Since at least Aug 7, 2025)
Director · Since at least May 9, 2022
Adrian BotDirector · Since at least Dec 16, 2025
All 24 people
PersonSeat
Ann K DonohueVP Finance · May 7, 2019 – May 27, 2021 · Past
Aymeric SallinDirector · Jun 21, 2016 – Jan 2, 2024 · Past
Blaine DavisChief Financial Officer · Since at least Nov 13, 2023
Christopher M JewellChief Scientific Officer · Nov 13, 2023 – Jan 10, 2025 · Past
Emily EnglishChief Operations Officer · Since at least Apr 9, 2024
Leysan ShaydullinaDirector · Jun 21, 2016 – Jun 21, 2016 · Past
Matthew BartholomaeGeneral Counsel, Secretary · Since at least Nov 5, 2026
Michael SingerDirector · Since at least Nov 5, 2026
Nishan de SilvaDirector · Since at least Nov 5, 2026
Patrick ZennerDirector · Since at least Oct 30, 2025
Peter KellerChief Business Officer · Jun 21, 2016 – Jul 7, 2017 · Past
Peter TraberHead of Research and Development · Since at least May 26, 2026
Takashi Kei KishimotoChief Scientific Officer · Jun 21, 2016 – May 30, 2023 · Past
Timothy SpringerDirector · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Cartesian Therapeutics, Inc.